2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies

2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies

Summary: Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael Sandherr, Jannik Stemler, Enrico Schalk, Tessa Hattenhauer, Marcus Hentrich, Bernd Hertenstein, Christian Hohmann, Sibylle C. Mellinghoff, Rebekka Mispelbaum, Christina Rieger, Martin Schmidt-Hieber, Rosanne Sprute, Guenter Weiss, Oliver A. Cornely, Larissa Henze, Cornelia Lass-Floerl, Gernot Beutel, Annika Y. Classen, Noemi F. Freise, Meinolf Karthaus, Philipp Koehler, Robert Krause, Julia Neuhann, Hans Martin Orth, Olaf Penack, Markus Schaich, Karsten Spiekermann, Sebastian Voigt, Florian Weissinger, Elena Busch
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:The Lancet Regional Health. Europe
Subjects:
Febrile Neutropenia
Cancer
Leukemia
Antimicrobial treatment
Algorithm
Evidence-based guideline
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776225000067
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary: Febrile Neutropenia is an emergency in the treatment of cancer patients. It requires prompt and evidence-based clinical and antimicrobial management. The implementation of standard operating procedures (SOP) across hospitals and outpatient cancer departments can improve the outcome of FN patients by reducing FN-related morbidity and mortality and by the continuation of cancer treatment. This guideline describes an evidence-based approach to risk stratification, epidemiology, diagnosis, and treatment. It is provided by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) and is an update of the 2017 version. Emerging aspects in epidemiology, diagnostic procedures, risk stratification, first-line antimicrobial treatment, empiric antifungal treatment and the duration of antimicrobial treatment are discussed and rated on evidence-based strength of recommendation and quality of evidence as described by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). By this, the aim of this guideline is to provide evidence-based recommendations on the management of febrile neutropenia in cancer patients for the practicing clinician.
ISSN:2666-7762

Similar Items